Is Cellectar Biosciences, Inc. (CLRB) a Buy, Sell, or Hold?
NASDAQ : CLRB
Cellectar Biosciences, Inc. — News
$2.6 USD
$0.06 (2.24%)
- Volume
- 29.92K
- Average Volume
- 1.07M
- Market Capitalization
- $20.77M
- P/E Ratio
- -0.35
- Dividend Yield
- 0.00%
- Price Target
- $11.00
- Year High
- $6.52
- Year Low
- $2.20
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.90
| Source | Headline |
|---|---|
|
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026
FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the second quarter ended June 30, 2026, and provide a corporate update on August 13, 2026, at 8:30 a.m. globenewswire.com - 2026-07-30 08:05:00 |
|
Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers
Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in Relapsed/Refractory Multiple Myeloma globenewswire.com - 2026-07-15 07:30:00 |
|
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase 3 Confirmatory Clinical Trial in 4Q26 FLORHAM PARK, N. J. , June 01, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that efficacy results from a subset of patients treated with iopofosine I 131 immediately post-Bruton Tyrosine Kinase inhibitor (BTKi) therapy in the Company's Phase 2 CLOVER WaM clinical trial of iopofosine I 131 to treat relapsed or refractory (r/r) Waldenström macroglobulinemia (WM) will be highlighted today in a poster presentation at the American Society of Clinical Oncology Annual Meeting (ASCO) taking place May 29-June 2, 2026 in Chicago, Illinois. globenewswire.com - 2026-06-01 08:05:00 |
|
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy globenewswire.com - 2026-06-01 08:05:00 |
|
Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript
Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript seekingalpha.com - 2026-05-14 11:50:50 |
|
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U. globenewswire.com - 2026-05-14 07:15:00 |
|
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) globenewswire.com - 2026-05-14 07:15:00 |
|
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
FLORHAM PARK, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the first quarter ended March 31, 2026, and provide a corporate update on May 14, 2026, at 8:30 a.m. Eastern Time. globenewswire.com - 2026-05-11 08:05:00 |
